Biogenera SpA is focused on developing innovative gene-specific molecules aimed at addressing significant medical needs in oncology, metabolic diseases, and dermatological conditions. The company’s pipeline includes several targeted therapies, such as BGA002, which specifically inhibits the MYCN gene associated with aggressive tumors, including neuroblastoma, a leading cause of cancer-related deaths in children. BGA002 has successfully completed preclinical studies and has received orphan drug designation from both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA), facilitating expedited development for patients with MYCN-positive tumors. The company is also advancing BGA002 for use in severe adult cancers, including small cell lung cancer, which is notably linked to smoking.

In addition to BGA002, Biogenera is developing other gene-targeted therapies, such as BGA003 for MYC-positive tumors and BGA005 for Survivin-positive tumors, among others. The company is committed to conducting clinical trials across various phases to ensure the efficacy and safety of its products. With a strong emphasis on research and development in specialized areas, Biogenera aims to revolutionize treatment options for patients suffering from these challenging conditions, positioning itself as a pioneering biotech firm in the European market.

Italy

BIOGENERA SpA is a company operating in the biotechnology pharmaceutical sector, specialising in the research and development of new DNA-based patient-specific biotechnological medicines for the treatment of serious pathologies. Founded in 2008, with its headquarters in Bologna, BIOGENERA SpA has a multidisciplinary team of researchers and is supported by numerous University partnerships ( in particular, the University of Bologna) and other companies of the pharmaceutical sector.

Biogenera

Company Details